CN111201022A - 加波沙朵在治疗糖尿病及相关状况中的用途 - Google Patents

加波沙朵在治疗糖尿病及相关状况中的用途 Download PDF

Info

Publication number
CN111201022A
CN111201022A CN201880065399.8A CN201880065399A CN111201022A CN 111201022 A CN111201022 A CN 111201022A CN 201880065399 A CN201880065399 A CN 201880065399A CN 111201022 A CN111201022 A CN 111201022A
Authority
CN
China
Prior art keywords
pharmaceutically acceptable
acceptable salt
administered
hours
diabetes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880065399.8A
Other languages
English (en)
Chinese (zh)
Inventor
马修·杜林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ovid Therapeutics Inc
Original Assignee
Ovid Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ovid Therapeutics Inc filed Critical Ovid Therapeutics Inc
Publication of CN111201022A publication Critical patent/CN111201022A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN201880065399.8A 2017-08-04 2018-08-02 加波沙朵在治疗糖尿病及相关状况中的用途 Pending CN111201022A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762541260P 2017-08-04 2017-08-04
US62/541,260 2017-08-04
PCT/US2018/044973 WO2019028234A1 (en) 2017-08-04 2018-08-02 USE OF GABOXADOL IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS

Publications (1)

Publication Number Publication Date
CN111201022A true CN111201022A (zh) 2020-05-26

Family

ID=65230918

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880065399.8A Pending CN111201022A (zh) 2017-08-04 2018-08-02 加波沙朵在治疗糖尿病及相关状况中的用途

Country Status (10)

Country Link
US (2) US10813918B2 (enExample)
EP (1) EP3648762A4 (enExample)
JP (1) JP2020529440A (enExample)
KR (1) KR20200047557A (enExample)
CN (1) CN111201022A (enExample)
AU (1) AU2018309049A1 (enExample)
CA (1) CA3071939A1 (enExample)
IL (1) IL272414A (enExample)
MX (1) MX2020001342A (enExample)
WO (1) WO2019028234A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3071939A1 (en) 2017-08-04 2019-02-07 Ovid Therapeutics Inc. Use of gaboxadol in the treatment of diabetes and related conditions
KR20200069316A (ko) 2017-10-12 2020-06-16 노보 노르디스크 에이/에스 의료 요법에서의 세마글루타이드
MX2021005992A (es) 2018-11-21 2021-09-14 Certego Therapeutics Inc Gaboxadol para reducir el riesgo de suicidio y para alivio rápido de la depresión.
MX2022007715A (es) 2019-12-18 2022-07-19 Ovid Therapeutics Inc Gaboxadol para el tratamiento terapeutico del sindrome de delecion 1p36.
IL298334A (en) 2020-05-20 2023-01-01 Certego Therapeutics Inc Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders
EP4511030A2 (en) * 2022-04-20 2025-02-26 Aclipse Two Inc. Treatment of gastrointestinal diseases
WO2025049710A1 (en) * 2023-08-29 2025-03-06 Aclipse Two Inc. Pharmaceutical composition for use in the disease treatments

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1942185A (zh) * 2004-04-02 2007-04-04 H.隆德贝克有限公司 用加波沙朵治疗呼吸功能损伤
US20100093787A1 (en) * 2004-04-02 2010-04-15 H. Lundbeck A/S Treatment of impaired respiratory function with gaboxadol
CN103228142A (zh) * 2010-09-28 2013-07-31 加利福尼亚大学董事会 治疗代谢综合征相关疾病的gaba激动剂和治疗或预防i型糖尿病的gaba组合

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK270278A (da) 1977-06-20 1978-12-21 Krogsgaard Larsen P Cycliske aminosyrer
US4362731A (en) 1980-09-01 1982-12-07 Sandoz Ltd. Myotonolytic use of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridin-3-ol and derivatives thereof
US4353910A (en) 1981-11-27 1982-10-12 Kefalas A/S Derivatives of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridine-3-one, pharmaceutical compositions and methods of treatment
DE19525598C2 (de) 1995-07-13 1997-09-25 Max Planck Gesellschaft Schlafmittel
GB0402118D0 (en) 2004-01-30 2004-03-03 Merck Sharp & Dohme Polymorphic forms of a GABAA agonist
WO2006102093A1 (en) * 2005-03-18 2006-09-28 Transform Pharmaceuticals, Inc. Gaboxadol forms, compositions thereof, and related methods
DE102005020882A1 (de) * 2005-05-04 2006-11-09 Dömling, Alexander, Dr. Verwendung von Gaboxadol und Derivaten zur Behandlung von Kinase-induzierten Krankheiten
US20110046090A1 (en) 2005-10-31 2011-02-24 Braincells Inc. Modulation of neurogenesis with gaba agents and gaba analogs
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US7635710B2 (en) 2006-02-15 2009-12-22 Neurim Pharmaceuticals (1991) Ltd. Pyrone-indole derivatives and process for their preparation
RS55585B1 (sr) 2006-11-22 2017-06-30 Clinical Research Associates LLC Postupci za lečenje daunovog sindroma, krhkog x sindroma i autizma
TW200920358A (en) 2007-08-13 2009-05-16 Lundbeck & Co As H Method of treating stress-mediated depression
US20090143335A1 (en) 2007-10-29 2009-06-04 H. Lundbeck A/S Modified absorption formulation of gaboxadol
WO2009117367A1 (en) * 2008-03-18 2009-09-24 Bristol-Myers Squibb Company Method for treating cancers having high glucose requirements employing an sglt2 inhibitor and compositions thereof
WO2013024047A1 (en) * 2011-08-12 2013-02-21 Ascendis Pharma A/S High-loading water-soluble carrier-linked prodrugs
PT3151832T (pt) 2014-06-06 2021-06-15 Ovid Therapeutics Inc Métodos para aumentar a inibição tónica e tratar a insónia secundária
JP6491679B2 (ja) 2014-06-12 2019-03-27 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ Ｇａｂａａ受容体活性のモジュレーターとしてのイミダゾピリダジン誘導体
US10610504B2 (en) * 2014-12-23 2020-04-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Alpha-cell re-generation combined with conversion to beta cells
AU2016295138B2 (en) 2015-07-17 2021-11-04 Ovid Therapeutics Inc. Methods of treating developmental disorders with gaboxadol
US9682069B2 (en) * 2015-07-17 2017-06-20 Ovid Therapeutics Inc Methods of treating Dravet syndrome
US20170348232A1 (en) 2016-06-07 2017-12-07 Ovid Therapeutics Inc. Formulations of gaboxadol for treatment of angelman syndrome, fragile x syndrome and fragile x-associated tremor/ataxia syndrome
US9399034B1 (en) 2015-08-11 2016-07-26 Ovid Therapeutics Inc Methods of sedation during critical care treatment
US9351968B1 (en) 2015-09-09 2016-05-31 Ovid Therapeutics Inc Methods of treating developmental disorders using pipradrol
US20180042903A1 (en) 2016-08-11 2018-02-15 Ovid Therapeutics Inc. Methods and compositions for treatment of epileptic disorders
CA3071939A1 (en) 2017-08-04 2019-02-07 Ovid Therapeutics Inc. Use of gaboxadol in the treatment of diabetes and related conditions

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1942185A (zh) * 2004-04-02 2007-04-04 H.隆德贝克有限公司 用加波沙朵治疗呼吸功能损伤
US20100093787A1 (en) * 2004-04-02 2010-04-15 H. Lundbeck A/S Treatment of impaired respiratory function with gaboxadol
CN103228142A (zh) * 2010-09-28 2013-07-31 加利福尼亚大学董事会 治疗代谢综合征相关疾病的gaba激动剂和治疗或预防i型糖尿病的gaba组合

Also Published As

Publication number Publication date
JP2020529440A (ja) 2020-10-08
WO2019028234A1 (en) 2019-02-07
US20210030728A1 (en) 2021-02-04
US11291658B2 (en) 2022-04-05
CA3071939A1 (en) 2019-02-07
US10813918B2 (en) 2020-10-27
AU2018309049A1 (en) 2020-02-27
MX2020001342A (es) 2020-08-31
US20190038606A1 (en) 2019-02-07
IL272414A (en) 2020-03-31
KR20200047557A (ko) 2020-05-07
EP3648762A1 (en) 2020-05-13
EP3648762A4 (en) 2021-03-24

Similar Documents

Publication Publication Date Title
CN111201022A (zh) 加波沙朵在治疗糖尿病及相关状况中的用途
ES2942185T3 (es) Composiciones farmacéuticas que comprenden BI-1356 y metformina
US20070172525A1 (en) Anti-diabetic combinations
TW201206503A (en) Controlled release compositions with reduced food effect
US11813362B2 (en) Film-coated tablet comprising a triazine derivative for use in the treatment of diabetes
TWI327469B (en) Pharmaceutical composition
JP2008509145A (ja) 抗糖尿病性経口インスリン−ビグアニドの組み合わせ
CA3192584A1 (en) Antidiabetic pharmaceutical compositions and preparation method thereof
US20030224046A1 (en) Unit-dose combination composition for the simultaneous delivery of a short-acting and a long-acting oral hypoglycemic agent
KR20140045271A (ko) 제미글립틴 및 메트포르민을 포함하는 복합 제제 및 이의 제조방법
WO2014017833A1 (en) Composite formulation for oral administration comprising metformin and rosuvastatin
WO2020013777A2 (en) Tablet formulations comprising metformin and sitagliptin
HK40030383A (en) Use of gaboxadol in the treatment of diabetes and related conditions
US20150374688A1 (en) Solid oral pharmaceutical compositions comprising fixed dose combination of metformin and sitagliptin or salts thereof.
JP2004536841A (ja) コア製剤
US20080014261A1 (en) Non-narcotic biphasic release compositions and methods for treatment of coughing, sneezing, rhinorrhea, and/or nasal obstruction
EP3813801A2 (en) Extended release osmotic tablet dosage form comprising metformin and sitagliptin
Chandramohan et al. REVIEW ON DEVELOPMENT OF SUSTAINED RELEASE CAPSULES INCORPORATING MATRIX GRANULES OF GLIMEPIRIDE
US20080008772A1 (en) Narcotic biphasic release compositions and methods for treatment of coughing, sneezing, rhinorrhea, and/or nasal obstruction
TR2025002186T2 (tr) Evogli̇pti̇n ve metformi̇n i̇çeren oral bi̇leşi̇m formülasyonu ve bunun hazirlanmasina yöneli̇k yöntem
KR20220140343A (ko) 에보글립틴 및 메트포르민을 포함하는 경구용 복합제제 및 그의 제조방법
HK40039267A (en) Film-coated tablet comprising a triazine derivative for use in the treatment of diabetes
HK1137345A (en) Combination treatment for diabetes mellitus

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40030383

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20200526

WD01 Invention patent application deemed withdrawn after publication